Jump to content

Search the Community

Showing results for tags 'immunotherapy'.

More search options

  • Search By Tags

    Type tags separated by commas.
  • Search By Author

Content Type


    • Announcements, meetings and other resources
    • Primary hormone therapy
    • Secondary hormone therapy
    • Castrate Resistant Prostate Cancer
    • Metastatic
    • Very high risk
    • New agents
    • Every little bit helps
    • Radiation, diagnostic imaging, bones and other prostate cancer topics
    • Articles on other sites
    • My story
    • Any suggestions?
    • The lounge

Find results in...

Find results that contain...

Date Created

  • Start


Last Updated

  • Start


Filter by number of...

Found 13 results

  1. Webinar - Dr. Larry Fong Explains Immuno-Oncology Tue Oct 1,10 am AEST AnCan invites you to hear one of the World's leading cancer immunologists explain immuno-oncology ... free with no registration required. If you have questions for Dr. Fong, please submit in advance to info@ancan.org - NO personal case queries please. For more information and joining instructions, click here .
  2. Click here to view an interesting video discussing recent developments in the treatment of advanced prostate cancer.
  3. Click here to view an interesting video discussing recent developments in the treatment of advanced prostate cancer.
  4. Us TOO is one of the largest Prostate Cancer Education and Support organisations in the United States. Each month Us TOO publishes a monthly newsletter called the "Hotsheet". I would recommend that you sign up with Us TOO to get the Hotsheet emailed to you each month. Click here to read the December 2016 Hotsheet. I was interested in an article in the December 2016 Hotsheet about the results of a study of treatment with ipilimumab. Ipilimumab (trade name Yervoy), is a monoclonal antibody that works to activate the immune system by targeting CTLA-4, a protein receptor that downregulates the immune system. Ipilimumab is used to treat melanoma. Trials are now underway with other types of cancer, including prostate cancer. The study found that treatment with ipilimumab did not extend overall survival in asymptomatic or minimally symptomatic men with metastatic castration resistant prostate cancer. The study found an increase in progression free survival and in PSA response rates in one of the patient subsets. There may be some prostate cancer patients who respond to treatment with ipilimumab. The lead investigator Dr Tomasz Beer said that "the biggest takeaway from the study is that ipilimumab used in unselected patients did not produce a clinical benefit for patients overall. If we better understand which patients have tumours that are more responsive to a drug like ipilimumab , it might be possible to demonstrate a clinical benefit. But in unselected patients we were just not able to see that."
  5. You may have heard on the news in the last day or so about how Keytruda, a drug used for melanoma, has produced good results in clinical trials to treat patients with lung cancer. Preliminary studies suggest that some advanced prostate cancer patients may respond well to Keytruda and futher clinical trials with prostate cancer patients are being planned. Click here to read a news article about the results of the clinical trials with Keytruda and lung cancer patients.
  6. An excellent webinar by Dr Larry Fong of University of California, San Francisco
  7. Click here to read an article from Science Daily on a promising treatment that is being investigated by researchers at Houston Methodist Hospital. Note this article reports on the long term outcomes of a Phase 2 trial which was conducted between 1999 and 2003. A Phase 3 trial (which is required for this particular gene therapy to be approved by regulators) is already underway.
  8. Paul Edwards

    Ipilimumab - Severe Side Effects?

    Ipilimumab (brand name Yervoy) is an immunotherapy drug which has been approved for the treatment of melanoma. There are currently clinical trials being conducted to see whether Ipilimumab is effective in treating prostate cancer. The South Australian Medicines Evaluation Panel has provided data to the Pharmaceutical Benefits Advisory Committee about patients treated with Ipilimumab in South Australian public hospitals. Between 1 August 2013 to 8 December 2014, 56 patients were treated with Ipilimumab. 8 of these patients suffered severe refractory colitis as a side effect of their treatment with Ipilimumab and were admitted to hospital. The average stay in hospital for treatment of the side effects was 21 days. The Pharmaceutical Benefits Advisory Committee commented that it didn't expect as many serious adverse events when it approved Ipilimumab on the Pharmaceutical Benefits Scheme. This emerging data may make it harder for Ipilimumab to be approved for the treatment of prostate cancer. Immunotherapy: Treatment to stimulate or restore the ability of the immune system to fight infection and disease. Melanoma: a type of skin cancer. Severe Refractory Colitis: Severe Bowel Inflammation which is resistant to treatment. Reference: http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/2015-07/ipilimumab-psd-july-2015
  9. A Youtube video from the Mini Medical School for the Public series from the University of California San Francisco Patients with advanced prostate cancer are currently treated with combinations and sequences of immunotherapies, hormonal approaches and chemotherapy. Professor Charles Ryan, a medical oncologist at the University of California San Francisco covers the clinical and biological factors that drive treatment choice and sequence by physicians, and highlights how prostate cancer therapies are emblematic of the progress that is being made against cancer in general. Further, he addresses the challenges faced by patients and doctors and the research being done to address them. http://youtu.be/kQ4im2WQ75E [Although the talk was given in June 2014, most of it is still current as at October 2015]
  10. Novel combination therapy shows promise in mouse models of advanced prostate cancer Published in News Medicine on April 30, 2015 at 7:00 AM · Chemotherapy can be very effective against small prostate tumors. Larger prostate tumors, however, accumulate cells that suppress the body's immune response, allowing the cancer to grow despite treatment. Researchers at the University of California, San Diego School of Medicine now find that blocking or removing these immune-suppressing cells allows a special type of chemotherapy — and the immune cells it activates — to destroy prostate tumors. This novel combination therapy, termed chemoimmunotherapy, achieved near complete remission in mouse models of advanced prostate cancer. The study was published April 29 in Nature. Advanced or metastatic prostate cancer does not typically respond to chemotherapy. Prostate cancers also fail to respond to a promising new type of immunotherapy drugs, called checkpoint inhibitors, which disable cancer cells' cloaking mechanism so that a person's own immune system can better fight the tumor. This specific resistance is likely due in part to immunosuppressive B cells, which are more common in larger prostate tumors in mice, as well as in advanced and metastatic prostate cancer in humans. As the name suggests, these cells keep the immune system at bay, rendering most therapies ineffective and allowing malignant tumors to grow unchecked. In this study, researchers worked with three different mouse models of advanced prostate cancer. All three models were resistant to low doses of the chemotherapy drug oxaliplatin, which has the unique ability to activate cancer-killing immune cells. But when the researchers blocked the development or function of immunosuppressive B cells or removed them entirely before treating the mice with low-dose oxaliplatin, the prostate tumors were almost completely destroyed by the mice's own immune cells. The team got similar results when low-dose oxaliplatin was combined with a checkpoint inhibitor. "The presence of such B cells in human prostate cancer calls for clinical testing of this novel therapeutic approach," said Shabnam Shalapour, PhD, postdoctoral researcher and first author of the study. Prostate cancer is the second leading cause of cancer-related death in American men. About one in seven men will be diagnosed with prostate cancer during their lifetimes. "In addition to prostate cancer, similar immunosuppressive B cells can be detected in other human cancers," said senior author Michael Karin, PhD, Distinguished Professor of Pharmacology and Pathology at UC San Diego. "This indicates that B cell-mediated immunosuppression might be the reason several other cancers are also unresponsive to checkpoint inhibitors, raising the hope that chemoimmunotherapy will have broader applications for many cancer types." Source: University of California, San Diego
  11. On 20 March 2015, The New Prostate Cancer Infolink collaborated with the CureTalk network to coordinate a discussion with the well-known medical oncologist Maha Hussain, MD, of the University of Michigan on “Current trends in the management of advanced and late stage prostate cancer.” You can access a full audio recording of this discussion and a complete transcript by clicking on this link.
  12. Paul Edwards

    New Ipilimumab Trial in Australia

    Ipilimumab (brand name Yervoy) is an immunotherapy approach to the treatment of cancer. Ipilimumab was the first treatment ever proven to extend survival in patients with metastatic melanoma, the deadliest form of skin cancer, and has been approved by the Australian Pharmaceutical Benefits Scheme for that treatment. Ipilimumab was tested in two phase III trials as a treatment for advanced, castration-resistant prostate cancer. In the patients receiving Ipilimumab after docetaxel, the drug failed to improve overall survival. Results of the trial in which patients received Ipilimumab prior to chemotherapy are not yet available. Ipilimumab is also now being tested in several phase II trials. One of these trials is a “Safety and Efficacy Study of Ipilimumab 3 mg/kg Versus Ipilimumab 10 mg/kg in Subjects With Metastatic Castration Resistant Prostate Cancer Who Are Chemotherapy Naive”. Details of this trial are available at the ClinicalTrials.gov site Identifier: NCT02279862. The trial is being conducted at 6 Australian locations in Melbourne, Sydney and Perth. One of the Melbourne locations has commenced recruitment.
  13. alanbarlee

    Advances in Immunotherapy

    Trial Shows Safety of Prostvac Vaccine Therapy for Prostate Cancer Patients An international team of researchers has shown that a specific vaccine therapy that activates a patient’s immune response can be safely administered to prostate cancer patients. The Phase II clinical study, published in the European Urology journal, evaluated this new vaccine in patients who had advanced prostate cancer diagnosed by increased prostate-specific antigen (PSA) and no visible metastasis, and whose cancer was resistant to hormone therapy. Furthermore, patients had already undergone surgery or radiation therapy. In the first part of the study, patients received PROSTVAC-V/TRICOM and PROSTVAC-F/TRICOM. The first is a vaccine that originates from a modified vaccinia virus that produces the PSA protein, helping to direct the patient’s immune response towards the PSA present in their prostate cancer cells. Additionally, this virus is genetically modified to produce 3 other proteins that augment the immune system’s capacity to locate and destroy cancer cells. PROSTVAC-F derives from the fowlpox virus and is endowed with the same genetic profile as PROSTAC-V, however it is administered several times to enhance the patient’s immune system. Men who enrolled in the trial were treated with one cycle of PROSTVAC-V/TRICOM followed by PROSTVAC-F/TRICOM for multiple cycles in combination with GM-CSF, a protein known to augment and activate some white blood cells. The results showed that after the first six months of therapy, 63% of patients had no disease progression and minimal toxic side effects. Before the treatment, the median PSA velocity was 0.13 log (PSA)/month, when compared to median post-treatment velocity of 0.09 log (PSA)/month. In the second half of the trail, patients received hormone therapy together with the PROSTVAC-VF/TRICOM combination, with 74% of subjects experiencing a complete response after seven months of follow up. “Previous studies by the ECOG-ACRIN Cancer Research Group and others have shown it is optimal to explore agents like PROSTVAC that harness the body’s own defenses in shutting down cancer. With our current findings demonstrating the safe use of combination vaccine therapy earlier in the course of prostate cancer progression, we are laying the groundwork for future immunotherapy options for this patient population,” lead author Robert S. DiPaola, MD, Cancer Institute of New Jersey Director, said in a news release.
  • Create New...